secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001558370-23-009944
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS reports Q1 2023 results, FDA clears IND for Alzheimer's candidate PMN310
-------------------------------------------------------------------------------

- FDA cleared IND for lead therapeutic candidate PMN310 for Alzheimer's disease; phase 1 enabling activities underway.
- Cash and cash equivalents of $3.3M as of March 31, 2023, down from $5.9M at December 31, 2022.
- Net loss of $5.0M for Q1 2023 compared to $2.1M in Q1 2022, driven by increased R&D spending on PMN310.
- R&D expenses rose to $3.5M from $1.9M YoY, primarily for drug product manufacturing and IND filing costs.
- Preclinical data presented at AD/PD and AAN conferences showing PMN310 selectivity and memory protection in AD models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/0001558370-23-009944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/pmn-20230515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer